Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Pharmaceutical Design

Volume 18 Issue 20
ISSN: 1381-6128
eISSN: 1873-4286

 

   All Titles

  Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
  pp.2883-2890 (8) Authors: Vladimir Krystof, Sonja Baumli, Robert Furst
 
 
      Abstract

Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.

 
  Keywords: Cancer, inflammation, kinase, P-TEFb, inhibitor, therapeutics, angiogenesis, cyclin-dependent kinases (CDKs), anticancer activity, chromosome condensation
  Affiliation: Laboratory of Growth Regulators, Palacky University, Slechtitelu 11, 78371, Olomouc, Czech Republic.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers